VERV

Verve Therapeutics Inc

14.47 0.96 (7.08%)

Kursy podawane z opóźnieniem przez NASDAQ, w USD Rynek otwarty

Trade

14.47

14.59

Najlepsze

@DeepNews

eToro

8 dni temu

$VERV (Verve Therapeutics Inc) Verve Therapeutics (NASDAQ:VERV) Lifted to Hold at Zacks Investment Research Verve Therapeutics (NASDAQ:VERV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. www.defenseworld.net/2022/05/18/verve-therapeutics-nasdaqverv-lifted-to-hold-at-zacks-investment-research-2.html

Przetłumacz

Verve Therapeutics (NASDAQ:VERV) Lifted to Hold at Zacks Investment Research

www.defenseworld.net

Verve Therapeutics (NASDAQ:VERV – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic […]

@DeepNews

eToro

13 dni temu

$VERV (Verve Therapeutics Inc) FY2022 EPS Estimates for Verve Therapeutics, Inc. (NASDAQ:VERV) Cut by Analyst Verve Therapeutics, Inc. (NASDAQ:VERV) – Equities researchers at Jefferies Financial Group cut their FY2022 earnings estimates for shares of Verve Therapeutics in a research report issued... Pokaż więcej

Przetłumacz

FY2022 EPS Estimates for Verve Therapeutics, Inc. (NASDAQ:VERV) Cut by Analyst

www.defenseworld.net

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Rating) – Equities researchers at Jefferies Financial Group cut their FY2022 earnings estimates for shares of Verve Therapeutics in a research report issued on Tuesday, May 10th. Jefferies Financial Group analyst E. Yang now expects that the company will earn ($2.91) per share for the year, down from their […]

@DeepNews

eToro

14 dni temu

$VERV (Verve Therapeutics Inc) Verve Therapeutics (NASDAQ:VERV) Lifted to Hold at Zacks Investment Research Verve Therapeutics (NASDAQ:VERV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. www.defenseworld.net/2022/05/10/verve-therapeutics-nasdaqverv-lifted-to-hold-at-zacks-investment-research.html

Przetłumacz

Verve Therapeutics (NASDAQ:VERV) Lifted to Hold at Zacks Investment Research

www.defenseworld.net

Verve Therapeutics (NASDAQ:VERV – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course […]